Trial Profile

A Phase 1, Open-Label, Dose-Escalation Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dasatinib (Primary) ; Tretinoin (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions

Most Recent Events

09 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov
24 Mar 2015 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017, as reported by ClinicalTrials.gov.
24 Mar 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Jan 2016, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com